CAPN2 and cancer: Moreover, the non‐peptidomimetic calpain 2‐selective inhibitor, CNa 29, demonstrated a significant attenuation of cancer metastasis, accompanied by downregulation in proliferation, migration, and the EMT (Figure S14).